Aetna · Clinical coverage policy

Aetna Esophageal pH Monitoring coverage criteria

Aetna covers esophageal pH monitoring (catheter-based and the wireless Bravo capsule) plus combined intraluminal impedance testing (MII-pH and MII-EM) for documented or suspected GERD that is refractory to or failing PPI therapy, for pre-surgical anti-reflux evaluation, for post-fundoplication assessment, and for specific pediatric indications (including infant vomiting and pediatric GERD via pH-impedance). The key gate is appropriate timing relative to anti-secretory/PPI therapy per indication; airway pH, pharyngeal pH, airway impedance, and impedance testing for other indications (e.g., achalasia, laryngo-pharyngeal reflux) are experimental/investigational, as is the Bravo capsule for infant vomiting.

Policy CPB 0667 · Effective · Verify against the current Aetna policy before submitting — view source policy.

Payer

Aetna

Policy

CPB 0667

Prior auth

Confirm

Effective

January 1, 2026

This page reflects the coverage criteria captured from Aetna policy CPB 0667 and may not include every criterion, exception, or code — verify the complete bulletin before submitting.

What this means for the claim

The covered path, the next step to get it approved, and the specific way it denies — built only from this policy.

When does Aetna cover Esophageal pH Monitoring (CPT 91034), and what gets it denied?

Path
Aetna covers esophageal pH monitoring (catheter-based and the wireless Bravo capsule) plus combined intraluminal impedance testing (MII-pH and MII-EM) for documented or suspected GERD that is refractory to or failing PPI therapy, for pre-surgical anti-reflux evaluation, for post-fundoplication assessment, and for specific pediatric indications (including infant vomiting and pediatric GERD via pH-impedance). The key gate is appropriate timing relative to anti-secretory/PPI therapy per indication; airway pH, pharyngeal pH, airway impedance, and impedance testing for other indications (e.g., achalasia, laryngo-pharyngeal reflux) are experimental/investigational, as is the Bravo capsule for infant vomiting. Coverage criteria include: Esophageal pH monitoring is medically necessary to detect refractory reflux in members with chest pain after cardiac evaluation, using a symptom-reflux association scheme (preferably the symptom association probability calculation); the pH study is done AFTER a trial of proton pump inhibitor (PPI) therapy for at least 4 weeks.; Esophageal pH monitoring is medically necessary to document abnormal esophageal acid exposure in an endoscopy-negative member being considered for surgical anti-reflux repair; the pH study is done AFTER withholding the anti-secretory drug regimen for more than 1 week.; Esophageal pH monitoring is medically necessary to document concomitant gastro-esophageal reflux disease (GERD) in an adult-onset, non-allergic asthmatic suspected of having reflux-induced asthma; the pH study is done AFTER withholding anti-secretory drugs for more than 1 week. Note: a positive test does not prove causality.; Esophageal pH monitoring is medically necessary to evaluate a member with suspected otolaryngologic manifestations (chronic cough, laryngitis, pharyngitis) of GERD AFTER symptoms have failed to respond to at least 4 weeks of PPI therapy; the pH study is done WHILE the member continues taking their anti-secretory drug regimen (to document the adequacy of therapy).; Esophageal pH monitoring is medically necessary to evaluate vomiting in infants up to 3 months of age.; Esophageal pH monitoring is medically necessary to evaluate members after anti-reflux surgery who are suspected to have ongoing abnormal reflux; the pH study is done AFTER withholding the anti-secretory drug regimen for more than 1 week.; Esophageal pH monitoring is medically necessary to evaluate members with either normal or equivocal endoscopic findings AND reflux symptoms refractory to PPI therapy; the pH study is done EITHER after withholding the anti-secretory drug regimen for 1 week or more (if done to confirm excessive acid exposure) OR while taking the anti-secretory drug regimen (if symptom-reflux correlation is to be scored).; The Bravo pH Monitoring System (disposable capsule pH monitor) is considered an acceptable alternative to standard catheter-based ambulatory pH monitoring for ALL of the medically necessary indications listed above, EXCEPT for evaluating vomiting in infants.; Multi-channel intraluminal pH impedance testing is medically necessary for evaluation of GERD in children and adolescents 18 years of age or younger.; Multi-channel intraluminal impedance combined with esophageal manometry (MII-EM) is medically necessary for evaluation of individuals with ONE of: refractory dysphagia/heartburn/regurgitation; OR unexplained non-cardiac chest pain; OR pre-operative evaluation before anti-reflux surgery.; Multi-channel intraluminal impedance combined with pH testing (MII-pH) is medically necessary for evaluation of individuals with gastro-esophageal reflux (GER) disease AND who have an incomplete or no response to acid-suppressive therapy with a proton pump inhibitor AND who have normal endoscopic findings; AND for evaluation of atypical GER symptoms (e.g., chronic cough).. Applies to 5 codes: 91034, 91035, 91037, 91038, 91010.
Action
Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source.
Trap
Policy exclusions and limitations: The Bravo pH Monitoring System is experimental, investigational, or unproven for evaluating vomiting in infants, because it has not been approved for use in this age group.; Esophageal pH recording is experimental, investigational, or unproven for all other indications, including: to detect or verify reflux esophagitis in adults (this is an endoscopic diagnosis).; Esophageal pH recording is experimental, investigational, or unproven to evaluate 'alkaline reflux' in adults.; Esophageal pH recording is experimental, investigational, or unproven to identify eosinophilic esophagitis in children with esophageal atresia.; Esophageal pH recording is experimental, investigational, or unproven to titrate PPI dosing in the management of Barrett's esophagus.; Airway pH monitoring is experimental, investigational, or unproven for detection of laryngo-pharyngeal reflux and other indications.; Pharyngeal pH monitoring is experimental, investigational, or unproven for diagnosis of extra-esophageal reflux disease.; Measurement of airway impedance is experimental, investigational, or unproven for diagnosis of gastroesophageal reflux or aspiration, and for prediction of extraesophageal airway inflammation.; Multichannel intraluminal impedance testing is experimental, investigational, or unproven for all other indications (e.g., achalasia, and laryngo-pharyngeal reflux). Claims may be denied when the requested service falls under these.

Source: Aetna CPB 0667 — Esophageal pH Monitoring

Coverage criteria

  • Esophageal pH monitoring is medically necessary to detect refractory reflux in members with chest pain after cardiac evaluation, using a symptom-reflux association scheme (preferably the symptom association probability calculation); the pH study is done AFTER a trial of proton pump inhibitor (PPI) therapy for at least 4 weeks.
  • Esophageal pH monitoring is medically necessary to document abnormal esophageal acid exposure in an endoscopy-negative member being considered for surgical anti-reflux repair; the pH study is done AFTER withholding the anti-secretory drug regimen for more than 1 week.
  • Esophageal pH monitoring is medically necessary to document concomitant gastro-esophageal reflux disease (GERD) in an adult-onset, non-allergic asthmatic suspected of having reflux-induced asthma; the pH study is done AFTER withholding anti-secretory drugs for more than 1 week. Note: a positive test does not prove causality.
  • Esophageal pH monitoring is medically necessary to evaluate a member with suspected otolaryngologic manifestations (chronic cough, laryngitis, pharyngitis) of GERD AFTER symptoms have failed to respond to at least 4 weeks of PPI therapy; the pH study is done WHILE the member continues taking their anti-secretory drug regimen (to document the adequacy of therapy).
  • Esophageal pH monitoring is medically necessary to evaluate vomiting in infants up to 3 months of age.
  • Esophageal pH monitoring is medically necessary to evaluate members after anti-reflux surgery who are suspected to have ongoing abnormal reflux; the pH study is done AFTER withholding the anti-secretory drug regimen for more than 1 week.
  • Esophageal pH monitoring is medically necessary to evaluate members with either normal or equivocal endoscopic findings AND reflux symptoms refractory to PPI therapy; the pH study is done EITHER after withholding the anti-secretory drug regimen for 1 week or more (if done to confirm excessive acid exposure) OR while taking the anti-secretory drug regimen (if symptom-reflux correlation is to be scored).
  • The Bravo pH Monitoring System (disposable capsule pH monitor) is considered an acceptable alternative to standard catheter-based ambulatory pH monitoring for ALL of the medically necessary indications listed above, EXCEPT for evaluating vomiting in infants.
  • Multi-channel intraluminal pH impedance testing is medically necessary for evaluation of GERD in children and adolescents 18 years of age or younger.
  • Multi-channel intraluminal impedance combined with esophageal manometry (MII-EM) is medically necessary for evaluation of individuals with ONE of: refractory dysphagia/heartburn/regurgitation; OR unexplained non-cardiac chest pain; OR pre-operative evaluation before anti-reflux surgery.
  • Multi-channel intraluminal impedance combined with pH testing (MII-pH) is medically necessary for evaluation of individuals with gastro-esophageal reflux (GER) disease AND who have an incomplete or no response to acid-suppressive therapy with a proton pump inhibitor AND who have normal endoscopic findings; AND for evaluation of atypical GER symptoms (e.g., chronic cough).

Covered codes

Codes listed in this Aetna policy. Check each one's prior-authorization verdict and Medicare rate:

Frequently asked questions

When does Aetna cover Esophageal pH Monitoring (CPT 91034), and what gets it denied?
Aetna covers esophageal pH monitoring (catheter-based and the wireless Bravo capsule) plus combined intraluminal impedance testing (MII-pH and MII-EM) for documented or suspected GERD that is refractory to or failing PPI therapy, for pre-surgical anti-reflux evaluation, for post-fundoplication assessment, and for specific pediatric indications (including infant vomiting and pediatric GERD via pH-impedance). The key gate is appropriate timing relative to anti-secretory/PPI therapy per indication; airway pH, pharyngeal pH, airway impedance, and impedance testing for other indications (e.g., achalasia, laryngo-pharyngeal reflux) are experimental/investigational, as is the Bravo capsule for infant vomiting. Coverage criteria include: Esophageal pH monitoring is medically necessary to detect refractory reflux in members with chest pain after cardiac evaluation, using a symptom-reflux association scheme (preferably the symptom association probability calculation); the pH study is done AFTER a trial of proton pump inhibitor (PPI) therapy for at least 4 weeks.; Esophageal pH monitoring is medically necessary to document abnormal esophageal acid exposure in an endoscopy-negative member being considered for surgical anti-reflux repair; the pH study is done AFTER withholding the anti-secretory drug regimen for more than 1 week.; Esophageal pH monitoring is medically necessary to document concomitant gastro-esophageal reflux disease (GERD) in an adult-onset, non-allergic asthmatic suspected of having reflux-induced asthma; the pH study is done AFTER withholding anti-secretory drugs for more than 1 week. Note: a positive test does not prove causality.; Esophageal pH monitoring is medically necessary to evaluate a member with suspected otolaryngologic manifestations (chronic cough, laryngitis, pharyngitis) of GERD AFTER symptoms have failed to respond to at least 4 weeks of PPI therapy; the pH study is done WHILE the member continues taking their anti-secretory drug regimen (to document the adequacy of therapy).; Esophageal pH monitoring is medically necessary to evaluate vomiting in infants up to 3 months of age.; Esophageal pH monitoring is medically necessary to evaluate members after anti-reflux surgery who are suspected to have ongoing abnormal reflux; the pH study is done AFTER withholding the anti-secretory drug regimen for more than 1 week.; Esophageal pH monitoring is medically necessary to evaluate members with either normal or equivocal endoscopic findings AND reflux symptoms refractory to PPI therapy; the pH study is done EITHER after withholding the anti-secretory drug regimen for 1 week or more (if done to confirm excessive acid exposure) OR while taking the anti-secretory drug regimen (if symptom-reflux correlation is to be scored).; The Bravo pH Monitoring System (disposable capsule pH monitor) is considered an acceptable alternative to standard catheter-based ambulatory pH monitoring for ALL of the medically necessary indications listed above, EXCEPT for evaluating vomiting in infants.; Multi-channel intraluminal pH impedance testing is medically necessary for evaluation of GERD in children and adolescents 18 years of age or younger.; Multi-channel intraluminal impedance combined with esophageal manometry (MII-EM) is medically necessary for evaluation of individuals with ONE of: refractory dysphagia/heartburn/regurgitation; OR unexplained non-cardiac chest pain; OR pre-operative evaluation before anti-reflux surgery.; Multi-channel intraluminal impedance combined with pH testing (MII-pH) is medically necessary for evaluation of individuals with gastro-esophageal reflux (GER) disease AND who have an incomplete or no response to acid-suppressive therapy with a proton pump inhibitor AND who have normal endoscopic findings; AND for evaluation of atypical GER symptoms (e.g., chronic cough).. Applies to 5 codes: 91034, 91035, 91037, 91038, 91010. Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source. Policy exclusions and limitations: The Bravo pH Monitoring System is experimental, investigational, or unproven for evaluating vomiting in infants, because it has not been approved for use in this age group.; Esophageal pH recording is experimental, investigational, or unproven for all other indications, including: to detect or verify reflux esophagitis in adults (this is an endoscopic diagnosis).; Esophageal pH recording is experimental, investigational, or unproven to evaluate 'alkaline reflux' in adults.; Esophageal pH recording is experimental, investigational, or unproven to identify eosinophilic esophagitis in children with esophageal atresia.; Esophageal pH recording is experimental, investigational, or unproven to titrate PPI dosing in the management of Barrett's esophagus.; Airway pH monitoring is experimental, investigational, or unproven for detection of laryngo-pharyngeal reflux and other indications.; Pharyngeal pH monitoring is experimental, investigational, or unproven for diagnosis of extra-esophageal reflux disease.; Measurement of airway impedance is experimental, investigational, or unproven for diagnosis of gastroesophageal reflux or aspiration, and for prediction of extraesophageal airway inflammation.; Multichannel intraluminal impedance testing is experimental, investigational, or unproven for all other indications (e.g., achalasia, and laryngo-pharyngeal reflux). Claims may be denied when the requested service falls under these.
Does Aetna require prior authorization for Esophageal pH Monitoring?
Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source.
What does Aetna exclude for Esophageal pH Monitoring?
Policy exclusions and limitations: The Bravo pH Monitoring System is experimental, investigational, or unproven for evaluating vomiting in infants, because it has not been approved for use in this age group.; Esophageal pH recording is experimental, investigational, or unproven for all other indications, including: to detect or verify reflux esophagitis in adults (this is an endoscopic diagnosis).; Esophageal pH recording is experimental, investigational, or unproven to evaluate 'alkaline reflux' in adults.; Esophageal pH recording is experimental, investigational, or unproven to identify eosinophilic esophagitis in children with esophageal atresia.; Esophageal pH recording is experimental, investigational, or unproven to titrate PPI dosing in the management of Barrett's esophagus.; Airway pH monitoring is experimental, investigational, or unproven for detection of laryngo-pharyngeal reflux and other indications.; Pharyngeal pH monitoring is experimental, investigational, or unproven for diagnosis of extra-esophageal reflux disease.; Measurement of airway impedance is experimental, investigational, or unproven for diagnosis of gastroesophageal reflux or aspiration, and for prediction of extraesophageal airway inflammation.; Multichannel intraluminal impedance testing is experimental, investigational, or unproven for all other indications (e.g., achalasia, and laryngo-pharyngeal reflux). Claims may be denied when the requested service falls under these.

Source

Aetna CPB 0667 — Esophageal pH Monitoring

Related

Need this Aetna approval drafted?

Ask D3 builds the documentation checklist and a ready-to-send request from this policy's criteria — cited, free, no signup.

Ask D3 Free

Coverage disclaimer

This page summarizes Aetna clinical-coverage criteria extracted from policy CPB 0667 for educational purposes. Coverage policies change and vary by individual plan. Always verify against Aetna's current policy before performing a procedure or submitting a claim. d3rx is not responsible for claim denials or reimbursement issues.